These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36212476)

  • 61. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
    Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
    Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
    [TBL] [Abstract][Full Text] [Related]  

  • 64. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification and Validation of METTL3-Related Molecules for Predicting Prognosis and Efficacy of Immunotherapy in Gastric Cancer Based on m6A Methylome and Transcriptome Sequencing Analysis.
    Chen S; Su X; Wang J; Zheng N; Tang Y; Peng G; Dong R; Lu F; Liu M; Zhao Y; Wu H
    Front Oncol; 2022; 12():935239. PubMed ID: 35965524
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retracted Article: LncRNA MALAT1 aggravates MPP-induced neuronal injury by regulating miR-212 in SH-SY5Y cells.
    Yuan D; Wang Q; Ding N; Du P; Peng L; Duan Z; Pan S
    RSC Adv; 2019 Jan; 9(2):690-698. PubMed ID: 35517595
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
    Front Oncol; 2022; 12():774307. PubMed ID: 35141159
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9.
    Xu Y; Zhang X; Hu X; Zhou W; Zhang P; Zhang J; Yang S; Liu Y
    Mol Med; 2018 Oct; 24(1):52. PubMed ID: 30285605
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer.
    Dong M; Shen W; Yang G; Yang Z; Li X
    Front Cell Dev Biol; 2022; 10():785058. PubMed ID: 35178386
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long noncoding RNA MALAT1-regulated microRNA 506 modulates ovarian cancer growth by targeting iASPP.
    Lei R; Xue M; Zhang L; Lin Z
    Onco Targets Ther; 2017; 10():35-46. PubMed ID: 28031721
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Knockdown of lncRNA MALAT1 ameliorates acute kidney injury by mediating the miR-204/APOL1 pathway.
    Lu HY; Wang GY; Zhao JW; Jiang HT
    J Clin Lab Anal; 2021 Aug; 35(8):e23881. PubMed ID: 34240756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 73. LncRNA MALAT1 up-regulates VEGF-A and ANGPT2 to promote angiogenesis in brain microvascular endothelial cells against oxygen-glucose deprivation via targetting
    Ren L; Wei C; Li K; Lu Z
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30038058
    [TBL] [Abstract][Full Text] [Related]  

  • 74. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
    Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
    J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
    [TBL] [Abstract][Full Text] [Related]  

  • 75. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Cell-Infiltration Characterization in Head and Neck Cancer.
    Yang Q; Xu F; Jian A; Yu H; Ye T; Hu W
    Front Cell Dev Biol; 2021; 9():803141. PubMed ID: 35198565
    [No Abstract]   [Full Text] [Related]  

  • 76. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long Noncoding RNA MALAT1 Functions as a Sponge of MiR-200c in Ovarian Cancer.
    Pa M; Naizaer G; Seyiti A; Kuerbang G
    Oncol Res; 2017 Sep; ():. PubMed ID: 28899458
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
    Hu G; He N; Cai C; Cai F; Fan P; Zheng Z; Jin X
    Pancreatology; 2019 Mar; 19(2):383-389. PubMed ID: 30670333
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
    Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.
    Wang Y; Zheng K; Xiong H; Huang Y; Chen X; Zhou Y; Qin W; Su J; Chen R; Qiu H; Yuan X; Wang Y; Zou Y
    Front Immunol; 2021; 12():762989. PubMed ID: 34975854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.